Abstract

DO.01.03

Prognostic factors in bevacizumab-therapy due to retinal vein occlusion

Ach T., Höh A. E., Schaal K. B., Scheuerle A. F., Dithmar S.
Universitäts-Augenklinik Heidelberg

Objective: Patients with macular edema (ME) due to retinal vein occlusion respond in different ways to treatment with bevacizumab. The aim was to evaluate predictive factors for intravitreal bevacizumab therapy.
Methods: 87 patients ((40 Central (CRVO) und 47 branch retinal vein occlusion (BRVO)) were treated with bevacizumab (2.5mg/0.1ml) intravitreally. Best-corrected visual acuity (BCVA), complete ophthalmological examination and OCT were performed at baseline and spaced on 6 weeks intervals. Re-injection was arranged when ME persisted or recurred in OCT. Mean follow-up was 23.37 weeks (range from 8 to 75 weeks). Age, central retinal thickness (CRT), BCVA and sex at baseline were analyzed with regard to their predictive value.
Results: Patients with complete resolution of ME 6 weeks after first injection (11 CRVO (group 1a), 20 BRVO (group 2a)) had a better long term BCVA prognosis than patients with persisting ME (29 CRVO (group 1b), 27 BRVO (group2b)). Group 1a had significantly thinner CRT in comparison with group 1b (629.5 µm vs 840.8 µm; p=0.003), a better baseline BCVA (0.82 logMAR ±0.80 vs 0.96 logMAR ±0.51;p=0.004) and were younger (64.18 years vs 71.97 years; p=0.025). Women benefit more often than men (37% women vs 22% men). Comparison of group 2a with group 2b showed no significant difference in baseline parameters.
Conclusions: Baseline parameters BCVA, CRT, age and sex are a prognostic value for intravitreal bevacizumab therapy in CRVO, but not in BRVO.

Copyright: Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.